肠道微生物β-glucuronidases影响内生态恒温,并通过各种疗法调节
Joshua B Simpson1, Morgan E Walker1, Joshua J Sekela1
1Department of Chemistry, University of North Carolina, Chapel Hill, NC, USA.
Cell host & microbe
|May 16, 2024
概括
肠道微生物 肠道微生物
科学领域:
- 微生物学和生物化学
- 代谢学 代谢学 代谢学
- 药理学 药理学是指药理学的学科.
背景情况:
- 激素和神经递质的干扰与各种疾病有关.
- 肠道微生物酶,特别是β-葡萄糖酶 (GUS),在内生代谢中发挥作用.
- 疾病发病和治疗反应的个体间变异性可能会受到GUS活动的影响.
研究的目的:
- 为了研究肠道微生物GUS酶在内生态恒温中所扮演的角色.
- 为了确定涉及激素和神经递质活性化的特定GUS酶.
- 探索FDA批准的药物在调节GUS活性以获得治疗益处方面的潜力.
主要方法:
- 在无菌和常规小鼠中进行多原子分析 (基因组学,代谢学).
- 在体外酶测试以表征GUS活性.
- 在体内研究涉及GUS抑制和内生水平的测量.
主要成果:
- 没有细菌的小鼠表现出较低水平的活性内生菌.
- 独特的肠道微生物GUS酶 (Loop 1和FMN GUS) 负责激素和神经递质的重新激活.
- 美国食品和药物管理局批准的药物通过向它们的催化循环,有效地抑制GUS酶.
- 在小鼠中抑制GUS会导致减少自由血清素和增加血清素葡萄化物.
结论:
- 肠道微生物酶对于维持内生生态平衡至关重要.
- 治疗调节GUS活动可以影响内生代谢.
- 这种代谢途径的破坏有助于治疗反应的个体间变化.
相关概念视频
Factors Affecting Drug Biotransformation: Biological
145
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
145
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173
Phase II Reactions: Glucuronidation
396
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
396
Drug Biotransformation: Overview
527
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
527
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318


